4170
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei C… Read more
4170 - Asset Resilience Ratio
4170 (4170) has an Asset Resilience Ratio of 39.03% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how 4170's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down 4170's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$162.80 Million | 39.03% |
| Total Liquid Assets | NT$162.80 Million | 39.03% |
Asset Resilience Insights
- Very High Liquidity: 4170 maintains exceptional liquid asset reserves at 39.03% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
4170 Industry Peers by Asset Resilience Ratio
Compare 4170's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for 4170 (2020–2024)
The table below shows the annual Asset Resilience Ratio data for 4170.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 37.38% | NT$154.30 Million | NT$412.78 Million | -2.07pp |
| 2023-12-31 | 39.45% | NT$178.36 Million | NT$452.10 Million | -0.40pp |
| 2022-12-31 | 39.85% | NT$185.64 Million | NT$465.82 Million | -0.78pp |
| 2021-12-31 | 40.63% | NT$200.18 Million | NT$492.64 Million | +24.16pp |
| 2020-12-31 | 16.47% | NT$60.80 Million | NT$369.09 Million | -- |